The Hong Kong startup combines 3D-printed reef tiles, biodiversity monitoring and long-term data to help companies manage their impact on marine ecosystems.
Updated
August 7, 2026 4:10 AM

Young corals growing on Archireef's 3D-printed terracotta reef tiles beneath the sea. IMAGE: ARCHIREFF
Anyone who has snorkeled over a coral reef has probably admired its vibrant colours and the marine life swimming between its branches. What is less visible is how easily these ecosystems can be damaged. Rising ocean temperatures and pollution continue to put reefs under pressure, while coastal development creates another threat. Construction can stir up sediment that settles on corals, blocking the sunlight they need and making it harder for damaged reefs to recover.
Protecting marine ecosystems is becoming a shared responsibility. Alongside scientists, governments and conservation groups, businesses whose operations affect the ocean are increasingly expected to understand, manage and reduce their environmental impact. They must also show regulators, banks and investors that they are meeting their environmental commitments.
Archireef helps businesses meet those demands. Founded by Vriko Yu, the Hong Kong-rooted B2B startup specializes in marine ecosystem restoration and ocean nature risk management. Drawing on years of research at the University of Hong Kong, Yu built the company to help organisations understand, measure and reduce their impact on marine ecosystems.
Yu describes Archireef as an “end-to-end ocean nature risk management company”.
“What we offer them is a credible way to meet those obligations and stand behind the results,” she says.
One of the company’s main tools for restoring damaged marine ecosystems is its flagship 3D-printed terracotta reef tile. The tiles provide a stable foundation where young corals can attach, grow and survive over time.
Archireef chose terracotta instead of concrete and other conventional materials because it is pH-neutral and does not release harmful chemicals into the water. Its surface also gives corals a suitable place to attach naturally.
Before placing a single tile in the ocean, the team studies the proposed restoration site to determine whether recovery is possible. It assesses the water quality, biodiversity and general health of the ecosystem. As Yu explains, restoration should begin only where nature has a realistic chance to recover.
“Restoration isn’t about replacing nature or engineering a reef into existence. It is about removing the barriers and giving a degraded system the conditions it needs to begin recovering on its own”, she says.
Once the team selects a site, divers carefully place the tiles on the seabed. Their curves, ridges and crevices imitate the structure of a natural coral reef, creating sheltered spaces for marine species. The design also helps limit sediment build-up, which can block sunlight and smother young corals.
.webp)
Archireef adjusts the shape of its reef tiles for each project.
“There’s no universal reef, so there’s no universal tile”, Yu says.
Instead of producing one standard model, the company adapts each design to the coral species, water conditions and surrounding marine environment. A coral restoration project in Hong Kong may therefore require a different tile from one in Saudi Arabia, even when the same manufacturing process is used.
“The biggest adaptation from site to site is usually the match between design, species and environment, not the manufacturing itself ”, Yu explains.

Although the reef tile is Archireef’s most recognizable innovation, Yu sees it as one part of a much broader service.
“The reef tile gets the attention because it’s tangible,” she says. “But the real product is the proof — defensible, audit-ready evidence of nature recovery that an organization can put in a disclosure and stand behind under scrutiny”.
Producing that evidence requires years of biodiversity monitoring. Long after the reef tiles have been installed, Archireef continues to track coral survival and the health of the surrounding marine ecosystem. Its monitoring methods include ecological surveys, AI-assisted species recognition, photogrammetry and environmental DNA testing.

Photogrammetry uses photographs to produce detailed 3D models of the reef. These models allow the team to measure changes in coral growth and reef structure over time.
Environmental DNA, commonly known as eDNA, offers another way to monitor marine biodiversity. Traditional ecological surveys often depend on divers recording the species they can see. eDNA testing instead examines traces of genetic material left in the water by marine organisms, including skin cells, mucus and waste.
By analyzing these traces, Archireef can detect species that may be hidden, difficult to identify or absent during a dive. This gives the company a more complete picture of the ecosystem and how it is changing.
For Archireef, the success of a coral reef restoration project is determined by what happens several years after installation.
“The indicators that matter aren’t the ones that look good on deployment day”, Yu says. “They’re the ones that show, two, three and five years on, whether a genuine ecosystem is establishing and sustaining itself”.
At the company’s first restoration site in Hoi Ha Wan, Hong Kong, around 90% of the transplanted corals remained alive four years after deployment. The long-term survival rate suggests that the ecosystem is recovering rather than simply appearing healthy during the early stages of the project.
Results like these have helped Archireef move beyond academic research and secure collaborations across the public and private sectors. In Hong Kong, the company has worked with government departments and public organisations responsible for coastal infrastructure and marine conservation.
Keep Reading
The CE approval opens Europe for Cornerstone Robotics as the company expands its global surgical robotics business
Updated
August 7, 2026 4:12 AM

A tray of surgical tools. PHOTO: UNSPLASH
As surgical robotics companies expand beyond domestic markets, regulatory approvals are becoming a critical part of global growth. Companies are no longer competing only on hardware and clinical performance. They are also competing on their ability to enter tightly regulated healthcare systems and build long-term hospital partnerships.
Hong Kong-based Cornerstone Robotics is now moving further into that phase of expansion after its Sentire Endoscopic Surgical System received CE Mark certification under the European Union’s Medical Device Regulation framework.
The approval allows the company to commercialize the system across European markets for minimally invasive procedures in general surgery, gynecology, thoracic surgery and urology. For surgical robotics companies, regulatory approvals often represent more than product validation. They also determine market access, hospital adoption opportunities and long-term commercial scale.
Cornerstone Robotics has already been building clinical operations in the UK ahead of the approval. Since 2025, the company has worked with Portsmouth Hospitals University NHS Trust on clinical investigations involving the Sentire Surgical System. According to the company, the system has been used across procedures involving urology, gynecology and gastrointestinal surgery. The company says the clinical investigation helped generate real-world data to support physician training, research and future adoption efforts.
Alongside the regulatory approval, Cornerstone Robotics is also expanding its local operations in Europe. The company established a UK subsidiary in 2025 and has been developing training, clinical support and after-sales service capabilities for hospitals using the system.
That operational buildout reflects a larger challenge inside surgical robotics. Hospitals adopting robotic systems often require ongoing clinical training, technical support and workflow integration alongside the hardware itself.
Cornerstone Robotics says its strategy centers around vertically integrated development across engineering, software, imaging and robotics systems. The company argues that this structure gives it greater control over product development, supply chain management and long-term operational stability.
Professor Samuel Au, Founder and CEO of Cornerstone Robotics, said: "Receiving CE Certification marks a major milestone in Cornerstone Robotics' evolution from a technology innovator to a global clinical solutions provider. From our first clinical investigation in Portsmouth, UK, to achieving European regulatory approval, each step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value. Looking ahead, we will continue expanding into key global markets and partnering with leading medical institutions to bring high-quality surgical robotic solutions to more physicians and patients worldwide."
The CE approval also comes several months after the company completed an oversubscribed financing round of approximately US$200 million in November 2025.
The funding and regulatory expansion together signal how surgical robotics companies are increasingly entering a more commercially focused stage of growth. Beyond research and development, companies are now investing more heavily in regulatory approvals, hospital partnerships, physician training and international operational infrastructure as competition expands across global healthcare markets.